Phase I First-in-Human Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of JNJ-74699157 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Summary
The purpose of this phase I study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in patients with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation.
General Information
NCT#: NCT04006301
Study ID: CR108652
Trial Phase: Phase I
Trial Sponsor: Janssen (Johnson & Johnson)
Therapies Used in This Trial: JNJ-74699157